GlassScriptPhysician profile
Lowell Satler
NPI 1255381778
$112,054.55
in general payments reported to CMS, 2019-2025
36 companies · $2,710 in 2025
The $2,710 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $7,701 · 2021: $17K · 2022: $19K · 2023: $6,200 · 2024: $9,586 · 2025: $2,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,202 · Consulting Fee: $7,050 · Travel and Lodging: $2,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,201.85 |
| Consulting Fee | $7,050.00 |
| Travel and Lodging | $2,244.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $51,477.62 | 2019-2025 | Amplatzer Talisman, Mitraclip, Coroflow |
| Astrazeneca Pharmaceuticals LP | $16,752.60 | 2019-2023 | Andexxa |
| Medtronic, INC. | $12,318.69 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Chiesi USA, INC. | $10,807.52 | 2019-2024 | Kengreal |
| Boston Scientific Corporation | $8,630.47 | 2019-2025 | Watchman Access System, Avvigo Guidance System, Synergy |
| Medtronic Vascular, INC. | $3,161.74 | 2019-2020 | |
| Edwards Lifesciences Corporation | $1,731.42 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Ancora Heart, INC. | $1,273.55 | 2022-2023 | Accucinch |
| Teleflex LLC | $975.29 | 2020-2025 | Manta, Guideliner, Turnpike |
| Amgen INC. | $747.54 | 2020-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $472.11 | 2020-2025 | Lifevest |
| Cardiovascular Systems INC. | $448.20 | 2019-2022 | |
| Abiomed | $318.52 | 2022-2024 | Impella |
| Jenavalve Technology, INC. | $292.80 | 2022-2023 | Jenavalve Pericardial Tavr System |
| E.R. Squibb & Sons, L.L.C. | $285.31 | 2019-2025 | Camzyos, Eliquis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $271.40 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $259.73 | 2019-2022 | |
| Heartflow, INC. | $203.31 | 2025 | |
| W. L. Gore & Associates, INC. | $187.66 | 2023 | Gore Tag Thoracic Branch Endoprosthesis |
| Novartis Pharmaceuticals Corporation | $184.15 | 2019-2025 | |
| Novo Nordisk INC | $162.97 | 2020-2024 | Wegovy, Rybelsus, Ozempic |
| Penumbra, INC. | $150.00 | 2019 | |
| Ge Healthcare | $142.59 | 2025 | |
| Philips North America LLC | $129.66 | 2019 | |
| Cardinal Health 200 LLC | $127.17 | 2019 | |
| Inari Medical, INC. | $114.76 | 2020 | |
| Biotronik INC. | $108.37 | 2019 | |
| Asahi Intecc USA, INC. | $88.01 | 2019-2025 | Asahi Coronary Wires, Asahi Peripheral Vascular Wires, Asahi Ptca Guide Wire |
| Cardiva Medical, INC. | $53.15 | 2019-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Celonova Biosciences, INC. | $49.20 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.46 | 2024-2025 | Jardiance |
| Shockwave Medical, INC | $28.35 | 2025 | |
| Atricure, INC. | $22.61 | 2022 | |
| Terumo Medical Corporation | $18.98 | 2024 | Angio-Seal |
| Recor Medical INC | $17.64 | 2025 | Paradise Ultrasound Renal Denervation System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lowell Satler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.